Neuronetics (NASDAQ:STIM) EVP Sells $21,446.70 in Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 16,005 shares of Neuronetics stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $1.34, for a total value of $21,446.70. Following the sale, the executive vice president owned 897,270 shares in the company, valued at $1,202,341.80. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

William Andrew Macan also recently made the following trade(s):

• On Thursday, February 26th, William Andrew Macan sold 3,427 shares of Neuronetics stock. The stock was sold at an average price of $1.35, for a total value of $4,626.45.
• On Thursday, February 12th, William Andrew Macan sold 14,120 shares of Neuronetics stock. The shares were sold at an average price of $1.65, for a total value of $23,298.00.
• On Tuesday, February 10th, William Andrew Macan sold 3,485 shares of Neuronetics stock. The stock was sold at an average price of $1.55, for a total value of $5,401.75.

Neuronetics Stock Performance

Shares of STIM stock opened at $1.46 on Wednesday. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02. The firm has a market cap of $100.80 million, a price-to-earnings ratio of -2.47 and a beta of 0.87. Neuronetics, Inc. has a 52 week low of $0.80 and a 52 week high of $4.97. The firm’s 50-day simple moving average is $1.58 and its two-hundred day simple moving average is $1.98.

Neuronetics (NASDAQ:STIM) last released its earnings results on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. Neuronetics had a negative net margin of 26.15% and a negative return on equity of 121.26%. The firm had revenue of $41.78 million during the quarter, compared to the consensus estimate of $40.84 million. As a group, equities analysts forecast that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Hedge Funds Weigh In On Neuronetics

Several hedge funds have recently made changes to their positions in STIM. Goldman Sachs Group Inc. raised its stake in shares of Neuronetics by 2,993.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock valued at $2,320,000 after purchasing an additional 610,014 shares during the period. Geode Capital Management LLC boosted its stake in Neuronetics by 172.3% in the 2nd quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock worth $3,068,000 after purchasing an additional 556,268 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in Neuronetics in the 2nd quarter worth about $34,000. Intech Investment Management LLC purchased a new position in Neuronetics during the 2nd quarter valued at about $64,000. Finally, JPMorgan Chase & Co. increased its position in shares of Neuronetics by 195,023.5% during the second quarter. JPMorgan Chase & Co. now owns 66,342 shares of the company’s stock valued at $232,000 after buying an additional 66,308 shares during the period. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on STIM. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group lowered their price target on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Key Stories Impacting Neuronetics

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Company reported higher revenue, narrowed loss and set a 2026 outlook — this operational improvement and guidance can support valuation uplift. Neuronetics reports higher revenue, narrows loss, sets 2026 outlook
• Positive Sentiment: Major shareholder Jorey Chernett has been buying heavily (recent purchases total hundreds of thousands of shares across several days), signaling insider conviction and providing buying support. Neuronetics (NASDAQ:STIM) Major Shareholder Jorey Chernett Buys 169,472 Shares
• Neutral Sentiment: Board/management change — Dan Reuvers was appointed CEO, succeeding Keith Sullivan. Leadership changes introduce execution risk but may be neutral if transition is smooth. Neuronetics appoints Dan Reuvers as CEO, succeeding Keith Sullivan
• Neutral Sentiment: Analyses remain mixed — a Seeking Alpha piece calls STIM highly speculative but highlights revenue growth as a potential catalyst; this keeps sentiment bifurcated. Neuronetics: Highly Speculative, But Revenue Growth Could Drive The Stock Higher
• Neutral Sentiment: Short‑interest data released appears to contain errors (zero/NaN values), so no clear short‑pressure signal from official releases at this time.
• Negative Sentiment: Insider selling by executives and a director: EVP William Andrew Macan, EVP Steven Pfanstiel and Director Keith J. Sullivan sold shares on March 19th — such sales can be viewed negatively by the market even though insiders still retain large positions. SEC insider sale filings
• Negative Sentiment: Analyst moves and price‑target cuts: Canaccord trimmed its PT from $7 to $3 (still a buy), while other firms lowered ratings or maintained sell views — downward revisions and mixed analyst sentiment are pressuring the stock. MarketBeat STIM coverage (analyst updates)

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.